

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4745213
<b>Application Number:</b>	09436347
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	6491
<b>Title of Invention:</b>	TREATMENT OF HEMATOLOGIC MALIGNANCIES ASSOCIATED WITH CIRCULATING TUMOR CELLS USING CHIMERIC ANTI-CD20 ANTIBODY
<b>First Named Inventor/Applicant Name:</b>	CHRISTINE A. WHITE
<b>Customer Number:</b>	47553
<b>Filer:</b>	David Laurence Fitzgerald
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	27693-01201
<b>Receipt Date:</b>	05-FEB-2009
<b>Filing Date:</b>	09-NOV-1999
<b>Time Stamp:</b>	20:23:44
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	4726
Deposit Account	181260
Authorized User	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
-----------------	----------------------	-----------	----------------------------------	------------------	------------------

1	Information Disclosure Statement Letter	0525_IDS_05-Feb-09.pdf	76427 e63805e4ef1651709ba094ac26dc56cd199824b81	no	2
<b>Warnings:</b>					
<b>Information:</b>					
2	Information Disclosure Statement (IDS) Filed (SB/08)	0525_1449_05-Feb-09.pdf	103851 88ee0ffaa94958be50fbce730ad21be21ef98fc	no	4
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
3	Foreign Reference	EP00274394A2.pdf	1693469 6d72d452f8c5846ff554a080d793853b3cae22bb	no	24
<b>Warnings:</b>					
<b>Information:</b>					
4	Foreign Reference	WO_94-08601.pdf	1089595 701af80f946ce653a6437a4bda3940747d8402c	no	34
<b>Warnings:</b>					
<b>Information:</b>					
5	Foreign Reference	WO_98-42378-A1.pdf	1845783 b6fe1c4f9087d6ad897ba282c39878fedecc04ac	no	41
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	Alas_Anticancer_Res_2000.pdf	785798 c3dc96c20578a2b04ff4640494c4e9a418583e40	no	6
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Arranz_JCO_1998.pdf	583136 8ffec91d878485d77c4d0f66687cb7c0f55a1e4da3b	no	9
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Belhadj_Ann_Oncol_2004.pdf	126924 7b47b15ek3f8e13325c0d383b7b6e713aefc02	no	7
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Byrd_Ca_Biother_Radiopharm_1999.pdf	172987 23282b196446d4eb40787c31c6da1c0527d5a80	no	2

Warnings:					
Information:					
10	NPL Documents	Chow_Haematologica_2002.pdf	5941536 2631b599a8b6b6c0b0808ba12425481b14749805	no	11
Warnings:					
Information:					
11	NPL Documents	Eisenbeis_Clin_Ca_Res_2004_s can.pdf	1140842 105c515f6c801d3428b495e19c549c5e306b731	no	10
Warnings:					
Information:					
12	NPL Documents	Engert_Ann_Hematol_1998.pdf	221908 008802aab48844502a218040ee319a81fa2cccf	no	3
Warnings:					
Information:					
13	NPL Documents	Foran_Br_J_Haematol_1998.pdf	497216 281b1b1053d17c271651b16c4015cc0ef9de0847	no	2
Warnings:					
Information:					
14	NPL Documents	Fridrik_Ann_Oncol_1997.pdf	87694 c95a2c954efe1d10c40bc512403bae193c31b6ec	no	4
Warnings:					
Information:					
15	NPL Documents	Gianni_Blood_2000_scan.pdf	772909 3ecbb665aaw7191954fe960cc0b6300647d04e1	no	7
Warnings:					
Information:					
16	NPL Documents	Ginaldi_J_Clin_Pathol_1998.pdf	822446 91134b63876a92353dc8b0f5d995419eb02ca7a227	no	6
Warnings:					
Information:					
17	NPL Documents	Golay_Haematologica_2003.pdf	1081214 4113436c9e54a48861aa9899f5fb7c93a02d86f	no	11
Warnings:					
Information:					
18	NPL Documents	Gribben_NEJM_1991.pdf	775952 3284061f63cc044093aeb9843a0c5f6c6d56a19	no	8

<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Hillmen_Semin_Oncol_2004.pdf	136407 0781d7399bc95ebba81ee3a377a052902be350489	no	5
<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	IDEC_press_release_ASH_1996.pdf	38778 2726c6a186e491aefeb20c08b20eb1593151f13	no	3
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Imrie_Curr_Oncol_1999.pdf	1851363 f1e0718899eb1ed06ca30bdc0aa10ef9c330654	no	8
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Jazirehi_Oncogene_2005.pdf	331476 421d94189d03136328afaae023095cb223817bc	no	23
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Keating_Semin_Oncol_2000.pdf	335699 27145d4d08ebd211cc9088bc9337d1cae192ba4c	no	5
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	Maddy_Immunol_1989.pdf	1122768 e960861b5f2a0508c25fc612808b1219aefc454a	no	7
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	Marti_ANYAS_1992.pdf	805190 600c7d85837d9ea0e18f0584374ac0ed6847e368	no	5
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	Mazza_BMT_1999.pdf	508392 eb3aa1c0aa5062110557a0ff1a19c0865d87bd19	no	6
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	Nguyen_Eur_J_Haematol_1999.pdf	2432841 ca44d51c7a7a0e7d4da10070928b0d860815c22bc	no	8

<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	Piro_ASH_abst-2272_1997.pdf	425506 4b9175b479a8706c5565cab849ba62286c8074b	no	3
<b>Warnings:</b>					
<b>Information:</b>					
29	NPL Documents	Saville_TW_statement.pdf	370427 aac27742354e888ca8b63ba862bb613a765393d4	no	3
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	van_der_Kolk_ASH_1997.pdf	1625377 a590e6c2b0b1bed112f6c35a5a0f8e5c8c4db74	no	3
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	Witzig_Am_J_Clin_Path_1994.pdf	1383532 2ba055305e2634c76e6c8e8ba013cbed4e4d4e0	no	7
<b>Warnings:</b>					
<b>Information:</b>					
32	NPL Documents	Zhou_Chinese_Pharm_J_1995.pdf	183456 5c6d9f58023ca004a23b41e58a8ba9490e4bc99	no	3
<b>Warnings:</b>					
<b>Information:</b>					
33	NPL Documents	Berinstein_AACR_1997.pdf	35674 3f0309718c86cb006c599a0e4d7d5468423d7	no	1
<b>Warnings:</b>					
<b>Information:</b>					
34	NPL Documents	OBrien_JCO_2001.pdf	4723248 58574b34abf6eeeb6b26f841b673712b51ca58c83	no	6
<b>Warnings:</b>					
<b>Information:</b>					
35	Fee Worksheet (PTO-06)	fee-info.pdf	30468 42b6e67b51b6b6c7bf13c15c2f9bae4438b34d89	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			34160289		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.